CD4+ T-lymphocyte counts in HIV infection: are European standards applicable to African patients?

CD4+ lymphocyte count (CD4+ LC) is a widely used marker of Human Immunodeficiency Virus (HIV) immune impairment. Physiological lymphocytosis is frequently encountered in Africans. Therefore, we tried to determine if given CD4+ LC levels are of similar significance in European versus African HIV-infected individuals. Lymphocyte phenotyping of 750 HIV-infected adults was retrospectively analyzed. Three hundred and seventy patients were consecutively selected in Paris, France; 185 in Abidjan, Côte d'Ivoire; and 195 in Bobo-Dioulasso, Burkina Faso. In the three settings, lymphocyte phenotyping was performed by flow cytometry using similar protocols. Data from Abidjan and Bobo-Dioulasso were combined on the basis of geographic proximity and contrasted with those from Paris. Geometric mean levels of Total Lymphocyte Count (TLC), CD4+ LC, CD8+ lymphocyte count (CD8+ LC), and CD4:CD8 ratio, adjusted for percentage of CD4+ T-cells (%CD4+), were compared between Africans and Europeans. For a given %CD4+, TLC and CD4+ LC but not CD8+ LC tended to be about one third higher in West African than in French adults (p < 0.0001). Approximate equivalencies of absolute CD4+ counts in French and West African HIV-infected adults suggest that where thresholds of 200 and 500 CD4+ cells/microliter are applied in Europe, it might be appropriate to apply a threshold of approximately 250 and 700 CD4+ cells/microliter in West Africa, respectively. Establishing indicators of progression of HIV infection with locally appropriate thresholds may represent important steps toward improvement of HIV disease management in Africa.

[1]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[2]  J. Phair,et al.  A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. , 1995, The New England journal of medicine.

[3]  K. Holmes,et al.  USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Ward,et al.  Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses , 1995 .

[5]  B. Branson Early intervention for persons infected with human immunodeficiency virus. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[7]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[8]  H. Gayle,et al.  Clinical research, prophylaxis, therapy, and care for HIV disease in Africa. , 1993, American journal of public health.

[9]  J. Kouadio,et al.  Rapid and simple screening and supplemental testing for HIV‐1 and HIV‐2 infections in West Africa , 1993, AIDS.

[10]  A. Tsiatis,et al.  CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. , 1991, Annals of internal medicine.

[11]  P Bacchetti,et al.  Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. , 1991, BMJ.

[12]  A. Landay,et al.  Precision and accuracy of absolute lymphocyte counts. , 1989, Clinical immunology and immunopathology.

[13]  Gilles Hm Normal haematological values in tropical areas. , 1981 .

[14]  D S Stein,et al.  Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. , 1994, The Journal of infectious diseases.